Nexam Chemical announces the outcome of the rights issue

Nexam Chemical completed a rights issue of 21,577,544 shares raising approximately SEK 51.8 million before estimated issue costs of SEK 6.6 million (including ~SEK 3.0 million in underwriting compensation), at a subscription price of SEK 2.40. The company’s share count increases from 80,915,798 to 102,493,342 (dilution ~21.1%); 13,974,950 shares (≈SEK 33.5m, 64.8%) were subscribed by investors with/without rights and 7,602,594 shares (≈SEK 18.2m, 35.2%) were allotted to underwriters. The board will not increase the issue by an additional SEK 15.0m, underwriting compensation may be paid in cash or up to 1,261,748 new shares, and management says the proceeds will accelerate scale-up amid a commercial breakthrough in its Recycling business.

Analysis

Market structure: The SEK 51.8m rights issue (post-issue shares 102.49m; dilution ~21.1%) materially extends Nexam Chemical’s (NEXAM.ST) runway and signals the firm can accelerate scale-up of its Recycling additives into industrial production. Winners: existing large holders (who took top-down allotments), new strategic/industrial customers who gain supply security, and specialist equipment/service providers for scale-up; losers: short-term liquidity providers and pre-issue shareholders diluted ~21%. The implied post-money market cap at the SEK2.40 price is ~SEK 246m — small-cap risk with binary upside tied to commercial rollouts over 6–24 months.

Risk assessment: Tail risks include slower-than-expected customer conversion (operational integration), a need for a follow-on raise within 12 months (>SEK30m) causing >10% incremental dilution, or an adverse foreign investment ruling per Swedish screening rules. Immediate (days) effects: share volatility around BTA conversion (27 Feb) and underwriter compensation decision (16 Feb). Short-term (weeks–months): order announcements and H1 2026 production ramp; long-term (12–36 months): margin capture if polymer replacement displaces metals at scale. Hidden dependency: successful scale-up depends on OEM qualification cycles — revenues may lag PR timelines by 3–9 months.

Trade implications: Direct play is a size-constrained long in NEXAM.ST around SEK2.40 with a 12–24 month thesis tied to 2–4 commercial rollouts; use structured options where liquid (bull-call spreads) or protective puts to limit downside. Hedge with a modest short of Swedish small‑cap industrial exposure or by buying puts on a Small Cap Sweden index if Nexam becomes a liquidity outlier. Catalysts to watch: customer contract publications, monthly volume ramp, underwriters’ choice to take shares (16 Feb) and operational KPIs by end-Q2 2026.

Contrarian angles: Consensus may underweight intellectual property value and long-term EBITDA leverage from additives replacing metals; conversely, the market could be underestimating execution risk and the frequency of follow-on raises in capital‑intensive scale-ups. Historical parallel: small-cap specialty-chem names that hit industrial production often take 12–18 months to translate into meaningful free cash flow; if Nexam achieves two industrial customers within 6–12 months, upside is underappreciated. Unintended consequence: underwriter share compensation could add ~1.26m shares (~1.2% dilution) — watch for stock overhang and lock-up timing that can compress price near-term.

Key Decisions for Investors

• Establish a modest 2–3% portfolio long position in Nexam Chemical (NEXAM.ST) at or below SEK2.40, target 100–120% upside over 12–24 months conditional on 2+ announced industrial customer conversions; set strict stop-loss at -25% or immediate exit if company announces a follow-on capital raise >SEK30m within 12 months.
• If options are available, buy a 12-month bull-call spread sized to equal ~1–2% portfolio risk: buy 12‑month SEK3.00 call, sell SEK5.00 call (limits cost, targets 25–100%+ returns if commercialization accelerates); if spreads illiquid, buy shares and purchase 6‑month 20% OTM puts to cap downside.
• Short-term tactical: reduce exposure by 50% or hedge via buying puts on Swedish small-cap index if underwriters elect cash compensation and lock-up/overhang >1.5m shares (decision due 16 Feb) OR if BTA conversion (27 Feb) creates heavy selling; reassess after underwriter decision and any customer contract release within 60 days.
• Rotate 1% of portfolio from commodity polymer manufacturers into Nordic specialty/ESG chemicals (long book) to capture asymmetric upside if circular additives scale; avoid increasing exposure if no verified production volumes reported by end-Q2 2026.